药物生态学:肠道微生物群如何导致药物反应的差异。

Pharma[e]cology: How the Gut Microbiome Contributes to Variations in Drug Response.

作者信息

Trepka Kai R, Olson Christine A, Upadhyay Vaibhav, Zhang Chen, Turnbaugh Peter J

机构信息

Department of Microbiology & Immunology, University of California, San Francisco, California, USA; email:

Department of Medicine, University of California, San Francisco, California, USA.

出版信息

Annu Rev Pharmacol Toxicol. 2025 Jan;65(1):355-373. doi: 10.1146/annurev-pharmtox-022724-100847. Epub 2024 Dec 17.

Abstract

Drugs represent our first, and sometimes last, line of defense for many diseases, yet despite decades of research we still do not fully understand why a given drug works in one patient and fails in the next. The human gut microbiome is one of the missing puzzle pieces, due to its ability to parallel and extend host pathways for drug metabolism, along with more complex host-microbiome interactions. Herein, we focus on the well-established links between the gut microbiome and drugs for heart disease and cancer, plus emerging data on neurological disease. We highlight the interdisciplinary methods that are available and how they can be used to address major remaining knowledge gaps, including the consequences of microbial drug metabolism for treatment outcomes. Continued progress in this area promises fundamental biological insights into humans and their associated microbial communities and strategies for leveraging the microbiome to improve the practice of medicine.

摘要

药物是我们对抗许多疾病的第一道防线,有时甚至是最后一道防线。然而,尽管经过了数十年的研究,我们仍然没有完全理解为什么某种药物在一个患者身上有效,而在另一个患者身上却无效。人类肠道微生物群是缺失的拼图之一,因为它能够平行并扩展宿主的药物代谢途径,以及更复杂的宿主-微生物群相互作用。在此,我们重点关注肠道微生物群与心脏病、癌症药物之间已确立的联系,以及神经疾病的新数据。我们强调可用的跨学科方法,以及如何利用这些方法来填补主要的知识空白,包括微生物药物代谢对治疗结果的影响。该领域的持续进展有望为人类及其相关微生物群落带来基本的生物学见解,并有望利用微生物群改善医学实践的策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索